Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: PROTAC therapeutics - Arvinas

Next Previous
Search
Drug Profile

Research programme: PROTAC therapeutics - Arvinas

Alternative Names: ARCC-29; ARV-378; ARV-771; BET-PROTAC ARV-771; Hydrophobic Tagging small molecules - Arvinas; HyT small molecules - Arvinas; PROTAC ARV-771; PROTAC ARV-825; PROTACs - Arvinas; Protein-targeting chimeric molecules - Arvinas; Proteolysis Targeting Chimeric molecules - Arvinas

Latest Information Update: 28 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arvinas
  • Developer Arvinas; Yale University
  • Class Anti-inflammatories; Antineoplastics; Small molecules
  • Mechanism of Action Androgen receptor degradation enhancers; Estrogen receptor alpha degradation enhancers; Proteolysis; Ubiquitin protein ligase complex modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Breast cancer; Haematological malignancies; Inflammation; Prostate cancer; Solid tumours

Most Recent Events

  • 28 Jan 2025 No recent reports of development identified for preclinical development in Haematological-malignancies in USA
  • 28 Jan 2025 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
  • 10 Dec 2022 ARV 825 is still in preclinical trials for Haematological malignancies in USA

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top